Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 40 of 164 for:    PEMT

Expression of DMBT1 in Colorectal Cancer Patients (DMBT1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02901600
Recruitment Status : Completed
First Posted : September 15, 2016
Last Update Posted : September 15, 2016
Sponsor:
Information provided by (Responsible Party):
Lille Catholic University

Brief Summary:

Although colorectal cancer is a preventable and curable disease if early stage tumors are removed, it is still the fourth cause of cancer worldwide and the second leading cause of death in many industrialized countries. The 5-year survival is about 55% often due to a late detection. Then, the identification of sensitive and specific molecular markers is therefore a major challenge for early diagnosis and prognosis of this disease.

Preliminary work have reported variations in the expression of DMBT1 (deleted in malignant brain tumor 1), a glycoprotein co-secreted with mucins in the light of the glands, during several stages of colon carcinogenesis. The goal of this study is to study by mass spectrometry (MS), alterations in the repertoire of glycosylation of mucins from colorectal tumors of various stages, grades, and recurrence status.


Condition or disease Intervention/treatment
DMBT1 Protein, Human Colorectal Cancer Other: Detection of the expression of DMTB1 by immunohistochemistry

Layout table for study information
Study Type : Observational
Actual Enrollment : 145 participants
Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Modification of the Expression and the Localization of DMBT1 (Deleted in Malignant Brain Tumor 1) in Colorectal Cancer
Study Start Date : June 2013
Actual Primary Completion Date : June 2015
Actual Study Completion Date : November 2015

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Patients with colorectal cancer
Fresh tissue samples from individuals with colorectal carcinoma taken from the tumor as well as from resection margins will be used for the detection of a potential marker of carcinogenesis.
Other: Detection of the expression of DMTB1 by immunohistochemistry
Patients with adenomatous polyps
Fresh tissue samples from individuals with adenomatous polyps will be used for the detection of a potential marker of carcinogenesis.
Other: Detection of the expression of DMTB1 by immunohistochemistry
Control patients
Fresh tissue samples from individuals without colorectal carcinoma will be used as control.
Other: Detection of the expression of DMTB1 by immunohistochemistry



Primary Outcome Measures :
  1. Semi-quantitative determination of the histological expression of DMBT1 [ Time Frame: at baseline ]
    The expression of DMTB1 will be determined by observation of the slides after immunohistochemistry using an anti-DMBT1 antibody

  2. Determination of the histological localisation of DMBT1 [ Time Frame: at baseline ]
    The localisation of DMTB1 will be determined by observation of slides after immunohistochemistry using an anti-DMBT1 antibody



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Individuals with colorectal carcinoma, with polyps or without colonic pathology
Criteria

Inclusion Criteria:

  • for colon cancer: patients surgically treated for colorectal cancer at the Group of hospitals of the Catholic Institute of Lille.
  • for adenomatous polyps : patients treated for adenomatous polyps at the Group of hospitals of the Catholic Institute of Lille.
  • for controls: patients surgically treated for diverticular disease at the Group of hospitals of the Catholic Institute of Lille.

Exclusion Criteria:

  • none

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02901600


Sponsors and Collaborators
Lille Catholic University
Investigators
Layout table for investigator information
Principal Investigator: Adriana Mihalache, MD, PhD GHICL

Layout table for additonal information
Responsible Party: Lille Catholic University
ClinicalTrials.gov Identifier: NCT02901600     History of Changes
Other Study ID Numbers: RT-06
First Posted: September 15, 2016    Key Record Dates
Last Update Posted: September 15, 2016
Last Verified: September 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Lille Catholic University:
DMBT1 expression
Colorectal cancer

Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases